These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 6280902)

  • 21. Measurements of angiotensin converting enzyme in captopril-treated patients.
    Kamoun PP; Bardet JI; Di Giulio S; Grunfeld JP
    Clin Chim Acta; 1982 Feb; 118(2-3):333-6. PubMed ID: 6276050
    [No Abstract]   [Full Text] [Related]  

  • 22. Humoral and hemodynamic effects of increasing doses of captopril in patients with essential hypertension.
    Sassano P; Pedrinelli R; Magagna A; Abdel-Haq B; Salvetti A
    Am J Cardiol; 1982 Apr; 49(6):1574-6. PubMed ID: 6280486
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A discrepancy between the effects of a single oral dose of captopril on blood pressure, plasma renin activity, and serum angiotensin-converting enzyme levels.
    Lechi A; Covi G; Capuzzo MG; Lechi C; Minuz P; Delva P; Scuro LA
    Int J Clin Pharmacol Ther Toxicol; 1983 Nov; 21(11):569-74. PubMed ID: 6317579
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of captopril, an angiotensin-converting enzyme inhibitor, in normotensive sodium-replete volunteers.
    Shepherd AN; Campbell BC; Reid JL
    J Cardiovasc Pharmacol; 1982; 4(3):381-7. PubMed ID: 6177933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Converting enzyme inhibition in mild and moderate essential hypertension. II.
    Rasmussen S; Leth A; Ibsen H; Damkjaer Nielsen M; Nielsen F; Giese J
    Acta Med Scand; 1986; 219(1):29-36. PubMed ID: 3006449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hormonal changes with long-term converting-enzyme inhibition by captopril in essential hypertension.
    Matthews PG; McGrath BP; Johnston CI
    Clin Sci (Lond); 1979 Dec; 57 Suppl 5():135s-138s. PubMed ID: 232017
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term efficacy of angiotensin-converting-enzyme inhibition with captopril in mild-to-moderate essential hypertension.
    Stumpe KO; Overlack A; Kolloch R; Schreyer S
    Br J Clin Pharmacol; 1982; 14 Suppl 2(Suppl 2):121S-126S. PubMed ID: 6291563
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The long term effects of the oral converting enzyme inhibitor, captopril in hypertensive patients--the endocrinological study of its hypotensive mechanism (author's transl)].
    Ogihara T; Maruyama A; Naka T; Hata T; Mikami H; Nakamaru M; Gotoh S; Masuo K; Otsuka A; Tsuchiya T; Tabuchi Y; Ohde H; Kumahara Y; Iwanaga K; Yanaihara C; Ohkaru H; Yanaihara N
    Nihon Naibunpi Gakkai Zasshi; 1980 Oct; 56(10):1484-96. PubMed ID: 6256218
    [No Abstract]   [Full Text] [Related]  

  • 29. Induction of angiotensin I-converting enzyme in rat lung with captopril: the effect of adrenalectomy.
    Fyhrquist F; Grönhagen-Riska C; Forslund T; Tikkanen I
    Am J Cardiol; 1982 Apr; 49(6):1508-10. PubMed ID: 6280480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Competitive inhibitor binding assay (IBA) of captopril and other inhibitors of angiotensin converting enzyme.
    Tikkanen FF; Grönhagen-Riska C
    Scand J Urol Nephrol Suppl; 1984; 79():13-6. PubMed ID: 6089313
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute effects of captopril on serum angiotensin-converting enzyme activity, the renin-aldosterone system and blood pressure in patients with sarcoidosis.
    Mizuno K; Gotoh M; Matsui J; Nagasawa S; Fukuchi S
    Tohoku J Exp Med; 1983 May; 140(1):107-8. PubMed ID: 6306866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Attenuation of pressor responses to intracerebroventricular angiotensin I by angiotensin converting enzyme inhibitors and their effects on systemic blood pressure in conscious rats.
    Baum T; Becker FT; Sybertz EJ
    Life Sci; 1983 Mar; 32(12):1297-303. PubMed ID: 6300578
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The measurement of angiotensin-converting enzyme in subjects receiving captopril.
    Roulston JE; MacGregor GA
    N Engl J Med; 1980 Aug; 303(7):397. PubMed ID: 6248782
    [No Abstract]   [Full Text] [Related]  

  • 34. Altered blood pressure and renin responses to converting enzyme inhibition after aprotinin-induced kallikrein-kinin-system blockade.
    Overlack A; Stumpe KO; Kühnert M; Heck I
    Clin Sci (Lond); 1980 Dec; 59 Suppl 6():129s-132s. PubMed ID: 6160938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between angiotensin I blockade and antihypertensive properties of single doses of MK-421 and captopril in spontaneous and renal hypertensive rats.
    Sweet CS; Arbegast PT; Gaul SL; Blaine EH; Gross DM
    Eur J Pharmacol; 1981 Dec; 76(2-3):167-76. PubMed ID: 6174351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose response in captopril therapy of hypertension.
    Lijnen P; Fagard R; Staessen J; Verschueren LJ; Amery A
    Clin Pharmacol Ther; 1980 Sep; 28(3):310-5. PubMed ID: 6250759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of food on acute and chronic effects of captopril in essential hypertensive patients.
    Salvetti A; Pedrinelli R; Magagna A; Abdel-Haq B; Graziadei L; Taddei S; Stornello M
    J Cardiovasc Pharmacol; 1985; 7 Suppl 1():S25-9. PubMed ID: 2580172
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiotensin I-converting enzyme gene polymorphism and acute response to captopril in essential hypertension.
    Nakano Y; Oshima T; Watanabe M; Matsuura H; Kajiyama G; Kambe M
    Am J Hypertens; 1997 Sep; 10(9 Pt 1):1064-8. PubMed ID: 9324115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contribution of angiotensin I converting enzyme gene polymorphism and angiotensinogen gene polymorphism to blood pressure regulation in essential hypertension.
    Mondorf UF; Russ A; Wiesemann A; Herrero M; Oremek G; Lenz T
    Am J Hypertens; 1998 Feb; 11(2):174-83. PubMed ID: 9524045
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Captopril, an orally active angiotensin I converting enzyme inhibitor in the treatment of renovascular and essential hypertension.
    Holtzman E; Rosenthal T; Stern N; Knecht A; Yaron A
    Isr J Med Sci; 1982 May; 18(5):597-602. PubMed ID: 6284678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.